Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2026CancersOpen Access

Real-World Evidence of Atezolizumab Efficacy as Part of First-Line Treatment for Extensive-Stage SCLC in Bulgaria

View Full Paper
Ask AI
Bookmark
Share

Authors

MMManoela ManovaBIBoryana IvanovaRKRositsa Krasteva

Discussion

Loading...

Member takes

Overview

Real-world evidence shows atezolizumab improves progression-free survival in extensive-stage SCLC, suggesting effective treatment.

Key Points

  • The aim is to evaluate atezolizumab's efficacy in real-world settings for extensive-stage small cell lung cancer treatment.
  • Analyzed data from electronic health records of patients treated with atezolizumab and chemotherapy.
  • Focus on patients matching IMpower133 trial criteria for comparison.
  • Utilized the Danny Platform for data integration and analysis.
  • 302 patients were included in the analysis.
  • Real-world progression-free survival was 7.6 months, surpassing IMpower133's 5.2 months.
  • The objective response rate was lower at 38.7% compared to 65.4% in the IMpower133 trial.

Cite This Study

Manova et al. (2026) studied this question.

synapsesocial.com/papers/69cf5e2e5a333a821460c48ahttps://doi.org/10.3390/cancers18071129
View Full Paper
Ask AI
Bookmark
Share